Plus Therapeutics (PSTV) said Wednesday it has signed a manufacturing services agreement with SpectronRx to produce Rhenium Obisbemeda, a radiotherapy for central nervous system cancers.
Financial details weren't disclosed.
Under the agreement SpectronRx will use its facilities to produce late-stage clinical and commercial supplies of Rhenium Obisbemeda, the company said.
The partnership aims to strengthen supply chain redundancy for Plus Therapeutics, ensuring it can meet the demands of late-stage clinical trials and future commercial needs, the company said.
Shares of Plus Therapeutics were down 6.6% in recent Wednesday trading.
Price: 1.27, Change: -0.09, Percent Change: -6.62
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。